Released on: February 26, 2008, 2:45 am

Press Release Author: Thermo Fisher Scientific - Mass Spectrometry

Industry: Chemicals

Press Release Summary: Thermo Fisher Scientific Inc., the world leader in serving
science, today announced a collaborative partnership with the newly opened Vascular
Proteomics Group at the James Black Center, King\'s College London, headed by Dr.
Manuel Mayr. Started in June 2007, the facility is equipped with the powerful
combination of a Thermo Scientific LTQ Orbitrap XL high performance mass
spectrometer and the ETD-equipped Thermo Scientific LTQ XL system. This offers the
most advanced proteomics capabilities available to today\'s researchers.


Press Release Body: Thermo Fisher Scientific Inc., the world leader in serving
science, today announced a collaborative partnership with the newly opened Vascular
Proteomics Group at the James Black Center, King\'s College London, headed by Dr.
Manuel Mayr. Started in June 2007, the facility is equipped with the powerful
combination of a Thermo Scientific LTQ Orbitrap XL high performance mass
spectrometer and the ETD-equipped Thermo Scientific LTQ XL system. This offers the
most advanced proteomics capabilities available to today\'s researchers.

The James Black Center is a world-renowned research facility with a range of core
competencies including genomics, proteomics, mulitphoton confocal microscopy and
MRI. The Center is using the Thermo Scientific LTQ Orbitrap XL, a protein
identification and biomarker discovery platform, along with an LTQ linear ion trap
coupled with electron transfer dissociation (ETD) capability for advanced proteomic
research in cardiovascular medicine.

\"We are delighted that our new proteomics facility at the James Black Center will
feature cutting- edge technology dedicated to cardiovascular research.
Our primary focus will be on the ability of stem cells to affect cardiovascular
repair,\" said Dr. Mayr.

Professor Qingbo Xu, British Heart Foundation Professor at King\'s College London,
states that, \"This group has the potential to make a big impact in cardiovascular
proteomics. The Cardiovascular Division has just been awarded a £9m grant from the
British Heart Foundation, which will provide excellent research possibilities here
at King\'s College.\"

The Thermo Scientific LTQ Orbitrap XL provides unparalleled sensitivity in MS/MSn, a
rapid scan rate, high mass accuracy and up to 100k resolution power. Taking
advantage of the high ion storage capacity and fast cycle times of linear ion trap
technology, the Thermo Scientific LTQ XL with ETD enables researchers at Kings
College to conduct rapid alternating CID (Collisionally Induced Dissociation) and
ETD experiments in LC/MSn analysis of complex samples. By rapidly alternating the
two fragmentation techniques, it is possible to significantly increase proteome
coverage and have complete confidence in each protein identified.

At the opening, Thermo Fisher Scientific\'s UK Life Science sales manager, Eric
Winter, said \"Manuel Mayr and the Vascular Proteomics Group at King\'s College are on
the leading edge of proteomic research in cardiovascular medicine. We are proud to
provide complete workflow solutions for advanced protein discovery proteomics and
quantitation.\"

Together, Dr. Mayr and Thermo Fisher Scientific have already collaborated on
articles in Molecular and Cellular Proteomics and the Journal of the American
College of Cardiology, as well as a chapter in the Proteomics Protocols Handbook.

For more information about the Thermo Scientific proteomic solutions, please call +1
800-532-4752, e-mail analyze@thermo.com or visit www.thermo.com/proteomics

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving
science.

2008 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the
property of Thermo Fisher Scientific Inc. and its subsidiaries.

###

About Thermo Fisher Scientific:

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science,
enabling our customers to make the world healthier, cleaner and safer. With an
annual revenue rate of more than $9 billion, we employ 30,000 people and serve over
350,000 customers within pharmaceutical and biotech companies, hospitals and
clinical diagnostic labs, universities, research institutions and government
agencies, as well as environmental and industrial process control settings. Serving
customers through two premier brands, Thermo Scientific and Fisher Scientific, we
help solve analytical challenges from routine testing to complex research and
discovery. Thermo Scientific offers customers a complete range of high-end
analytical instruments as well as laboratory equipment, software, services,
consumables and reagents to enable integrated laboratory workflow solutions. Fisher
Scientific provides a complete portfolio of laboratory equipment, chemicals,
supplies and services used in healthcare, scientific research, safety and education.
Together, we offer the most convenient purchasing options to customers and
continuously advance our technologies to accelerate the pace of scientific
discovery, enhance value for customers and fuel growth for shareholders and
employees alike. Visit www.thermofisher.com

About Dr Manuel Mayr
Dr. Manuel Mayr received his first degree in medicine from the University of
Innsbruck, Austria, where he graduated \"sub ausspiciis presidentis rei publicae\",
the highest distinction awarded for academic education. From
1996-1998 he worked with Prof. Georg Wick at the Institute of Experimental
Pathology, Innsbruck, Austria on the role of heat shock proteins in atherosclerosis.
Beginning his postdoctoral studies, he joined Prof. Qingbo Xu\'s group at the
Institute of Biomedical Aging Research of the Austrian Academy of Sciences, working
in the area of animal models and cellular signalling in response to biomechanical
stress. In 2001, he moved together with Prof. Xu to London. At St. George\'s, he
developed his proteomic skills and obtained his PhD, entitled \"Cardiovascular
proteomics: Linking proteomic and metabolomic changes\" from the University of London
in 2005. In 2006, he spent a sabbatical in Prof. Peipei Ping\'s laboratory at the
University of California, Los Angeles, to further advance his skills in mass
spectrometry.
So far, he has published 45 peer-reviewed publications. This year, he was presented
the inaugural Michael Davies Early Career Award of the British Cardiovascular
Society for the best contribution by a basic scientist or clinical investigator in
the early part of their research career.



Web Site: http://www.thermo.com/proteomics

Contact Details: For further press information please contact: Laura Browne, The
Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire. CW4 8AA
United Kingdom Tel: + 44 1477 539539 Fax: +44 1606 1477 539540 E-mail:
thermo@scottpr.com